These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 19364815)

  • 21. HOXB7 promotes malignant progression by activating the TGFβ signaling pathway.
    Liu S; Jin K; Hui Y; Fu J; Jie C; Feng S; Reisman D; Wang Q; Fan D; Sukumar S; Chen H
    Cancer Res; 2015 Feb; 75(4):709-19. PubMed ID: 25542862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
    Pradeep CR; Zeisel A; Köstler WJ; Lauriola M; Jacob-Hirsch J; Haibe-Kains B; Amariglio N; Ben-Chetrit N; Emde A; Solomonov I; Neufeld G; Piccart M; Sagi I; Sotiriou C; Rechavi G; Domany E; Desmedt C; Yarden Y
    Oncogene; 2012 Aug; 31(31):3569-83. PubMed ID: 22139081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation.
    Wang S; Yuan Y; Liao L; Kuang SQ; Tien JC; O'Malley BW; Xu J
    Proc Natl Acad Sci U S A; 2009 Jan; 106(1):151-6. PubMed ID: 19109434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.
    Siegel PM; Dankort DL; Hardy WR; Muller WJ
    Mol Cell Biol; 1994 Nov; 14(11):7068-77. PubMed ID: 7935422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance.
    Meyer DS; Aceto N; Sausgruber N; Brinkhaus H; Müller U; Pallen CJ; Bentires-Alj M
    Oncogene; 2014 Jan; 33(3):398-402. PubMed ID: 23318421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation.
    Rivas MA; Tkach M; Beguelin W; Proietti CJ; Rosemblit C; Charreau EH; Elizalde PV; Schillaci R
    Breast Cancer Res Treat; 2010 Jul; 122(1):111-24. PubMed ID: 19760502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
    Muthuswamy SK; Siegel PM; Dankort DL; Webster MA; Muller WJ
    Mol Cell Biol; 1994 Jan; 14(1):735-43. PubMed ID: 7903421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.
    Shattuck DL; Miller JK; Carraway KL; Sweeney C
    Cancer Res; 2008 Mar; 68(5):1471-7. PubMed ID: 18316611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MET and MYC cooperate in mammary tumorigenesis.
    Welm AL; Kim S; Welm BE; Bishop JM
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4324-9. PubMed ID: 15738393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.
    Graveel CR; DeGroot JD; Su Y; Koeman J; Dykema K; Leung S; Snider J; Davies SR; Swiatek PJ; Cottingham S; Watson MA; Ellis MJ; Sigler RE; Furge KA; Vande Woude GF
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12909-14. PubMed ID: 19567831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer.
    Pontier SM; Huck L; White DE; Rayment J; Sanguin-Gendreau V; Hennessy B; Zuo D; St-Arnaud R; Mills GB; Dedhar S; Marshall CJ; Muller WJ
    Oncogene; 2010 Jun; 29(23):3374-85. PubMed ID: 20305688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice.
    Li YJ; Liu G; Xia L; Xiao X; Liu JC; Menezes ME; Das SK; Emdad L; Sarkar D; Fisher PB; Archer MC; Zacksenhaus E; Ben-David Y
    Oncotarget; 2015 Nov; 6(35):36943-54. PubMed ID: 26460950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.
    Koman IE; Commane M; Paszkiewicz G; Hoonjan B; Pal S; Safina A; Toshkov I; Purmal AA; Wang D; Liu S; Morrison C; Gudkov AV; Gurova KV
    Cancer Prev Res (Phila); 2012 Aug; 5(8):1025-35. PubMed ID: 22689915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta.
    Wang SE; Shin I; Wu FY; Friedman DB; Arteaga CL
    Cancer Res; 2006 Oct; 66(19):9591-600. PubMed ID: 17018616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
    Campbell MJ; Wollish WS; Lobo M; Esserman LJ
    In Vitro Cell Dev Biol Anim; 2002 Jun; 38(6):326-33. PubMed ID: 12513120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
    Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
    Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.
    Hutchinson JN; Jin J; Cardiff RD; Woodgett JR; Muller WJ
    Cancer Res; 2004 May; 64(9):3171-8. PubMed ID: 15126356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P95 HER2 fragments and breast cancer outcome.
    Tural D; Akar E; Mutlu H; Kilickap S
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.